PL2231689T3 - Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych - Google Patents

Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych

Info

Publication number
PL2231689T3
PL2231689T3 PL09702842T PL09702842T PL2231689T3 PL 2231689 T3 PL2231689 T3 PL 2231689T3 PL 09702842 T PL09702842 T PL 09702842T PL 09702842 T PL09702842 T PL 09702842T PL 2231689 T3 PL2231689 T3 PL 2231689T3
Authority
PL
Poland
Prior art keywords
deazapurine nucleosides
novel cytostatic
cytostatic
novel
deazapurine
Prior art date
Application number
PL09702842T
Other languages
English (en)
Polish (pl)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic filed Critical Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Publication of PL2231689T3 publication Critical patent/PL2231689T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00032—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by data exchange
    • H02J7/00036—Charger exchanging data with battery
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00047—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL09702842T 2008-01-18 2009-01-15 Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych PL2231689T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
PL2231689T3 true PL2231689T3 (pl) 2017-01-31

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09702842T PL2231689T3 (pl) 2008-01-18 2009-01-15 Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych
PL16174985T PL3133080T3 (pl) 2008-01-18 2009-01-15 Nowe cytostatyczne nukleozydy 7-deazapurynowe

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16174985T PL3133080T3 (pl) 2008-01-18 2009-01-15 Nowe cytostatyczne nukleozydy 7-deazapurynowe

Country Status (18)

Country Link
US (1) US8093226B2 (OSRAM)
EP (2) EP3133080B1 (OSRAM)
JP (2) JP5485172B2 (OSRAM)
CN (1) CN101977923B (OSRAM)
AU (1) AU2009204568B2 (OSRAM)
CA (1) CA2711384C (OSRAM)
CY (2) CY1118104T1 (OSRAM)
DK (2) DK2231689T3 (OSRAM)
ES (2) ES2693551T3 (OSRAM)
HR (2) HRP20161344T1 (OSRAM)
HU (2) HUE030767T2 (OSRAM)
LT (2) LT2231689T (OSRAM)
NZ (1) NZ586610A (OSRAM)
PL (2) PL2231689T3 (OSRAM)
PT (2) PT2231689T (OSRAM)
SI (2) SI2231689T1 (OSRAM)
TR (1) TR201815961T4 (OSRAM)
WO (1) WO2009089804A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA2759131C (en) * 2009-04-22 2017-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 7-deazapurine nucleosides for therapeutic uses
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3478701B1 (en) 2016-06-29 2022-08-10 Ustav organicke chemie a biochemie AV CR, v.v.i. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
MA56544A (fr) * 2019-06-18 2022-04-27 Taiho Pharmaceutical Co Ltd Nouveau compose ester d'acide phosphorique possedant un squelette pyrolo-pyrimidine ou sel pharmaceutiquement acceptable de celui-ci
EP4106763A1 (en) * 2020-02-17 2022-12-28 Katholieke Universiteit Leuven KU Leuven Research & Development Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (OSRAM) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
CA2537114C (en) * 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
US20080280842A1 (en) * 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
AU2009204568B2 (en) 2013-10-03
NZ586610A (en) 2012-08-31
EP3133080B1 (en) 2018-08-01
US20090203637A1 (en) 2009-08-13
LT3133080T (lt) 2018-11-12
JP5485172B2 (ja) 2014-05-07
CY1118104T1 (el) 2017-06-28
CN101977923B (zh) 2014-10-08
EP3133080A1 (en) 2017-02-22
SI2231689T1 (sl) 2016-11-30
CA2711384C (en) 2016-07-26
PT2231689T (pt) 2016-10-07
ES2693551T3 (es) 2018-12-12
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
EP2231689B1 (en) 2016-07-20
SI3133080T1 (sl) 2018-12-31
CY1121364T1 (el) 2020-05-29
JP2014058567A (ja) 2014-04-03
AU2009204568A1 (en) 2009-07-23
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
HRP20161344T1 (hr) 2016-11-18
DK2231689T3 (en) 2016-09-19
TR201815961T4 (tr) 2018-11-21
CA2711384A1 (en) 2009-07-23
US8093226B2 (en) 2012-01-10
HUE041598T2 (hu) 2019-05-28
HUE030767T2 (en) 2017-05-29
JP2011509949A (ja) 2011-03-31
EP2231689A1 (en) 2010-09-29
PL3133080T3 (pl) 2018-12-31
ES2598503T3 (es) 2017-01-27
CN101977923A (zh) 2011-02-16
LT2231689T (lt) 2016-10-25

Similar Documents

Publication Publication Date Title
HRP20181774T1 (hr) Novi citostatski 7-deazapurinski nukleosidi
IL210855A0 (en) Novel adenine derivatives
ZA201008829B (en) Nucleoside cyclicphosphates
PL2421879T3 (pl) Nowe nukleozydy 7-deazapurynowe do zastosowań terapeutycznych
IL213698A0 (en) Nucleoside phosphoramidates
ZA201104638B (en) Nucleoside analogs
IL200831A0 (en) Novel adenine compounds
IL205625A0 (en) Antiviral nucleoside compounds
EP2138497A4 (en) NEW ADENINE CONNECTION
IL213701A0 (en) Synthesis of purine nucleosides
IL210207A0 (en) Compounds having antiviral properties
IL213167A0 (en) Purine compounds
IL208351A0 (en) Antiviral therapy
GB0803707D0 (en) Antiviral agent
GB0723609D0 (en) Antiviral
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
ZA201005416B (en) Cytostatic composition
GB0816600D0 (en) Antiviral compounds
IL192335A0 (en) Antiviral compounds
GB0819528D0 (en) Antiviral compounds
GB0704852D0 (en) Furanose derivatives
GB0717955D0 (en) Preparation of modified nucleosides
GB0803654D0 (en) Buster brackets (KA-2 + KA-9)